Newron raises CHF27m Neurology specialist Newron Pharmaceuticals S.p.A. (Milan) has raised gross proceeds of CHF 27m through a private placement of new shares via an accelerated book-building process. more ➔
EU approves Roches atezolizumab for blad...Though not reaching the overall surival endpoint in Phase III, the European Commission has granted label extension for Roches checkpoint blocker Tecentriq in two types of metastatic bladder cancer … more ➔
Da Volterra bags €20m EIB investmentFrench microbiota specialist Da Volterra has received an EIB loan to speed up development of treatments that prevent antibiotic resistance and hospital acquired infections. more ➔
microRNA blocks life-threatening ARDSA team of US and German researchers has found that neutrophils secrete a regulatory RNA into lung tissue that protects against harmful inflammations. more ➔
Vesalius Biocapital and IFD launch life sc...Healthcare investor Vesalius Biocapital has created a new investment vehicle in collaboration with the Portuguese National Promotional bank (IFD) aimed at investing in Portuguese life science compan … more ➔
Immunocore nabs US$40m from Gates Foundati...British T cell receptor specialist Immunocore Ltd will receive a US$40m investment from the the Bill & Melinda Gates Foundation to develop immunotherapies that fight tuberculosis and HIV. … more ➔
CHMP candidate checkThe European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) published the results of its September meeting. more ➔
EMA rejects Santheras DMD drug The European Medicine Agencys CHMP has rejected a type II extension application to Santhera Pharmaceuticals coenzyme Q10 analogon idebenone (Raxone) as treatment for patients with Duchenne muscular … more ➔
Sophia Genetics raises US$30mArtificial intelligence (AI) specialist Sophia Genetics SA (St. Sulpice, Switzerland) raised US$30m in a series D round to foster global expansion of its cancer diagnostics annotation platform SOPHiA … more ➔
MS: Gut microbobes drive inflammationTwo research team independently report they have identified specific microbes in the gut of mice and of treatment-naive patients with multiple sclerosis (MS) regulating immune responses. Phase I trails … more ➔